Skip Ribbon Commands
Skip to main content
Sign In

26025 RNA Polymerase III Antibodies, IgG, Serum (RNAP)

RNA Polymerase III Antibodies, IgG, Serum (RNAP)
Test Code: RNAPSO
Synonyms/Keywords
RNA Polymerase III Ab, IgG, S
Useful For

Evaluating patients suspected of having systemic sclerosis, when used in conjunction with centromere and Scl70 antibodies.

Providing diagnostic and prognostic information in patients with systemic sclerosis.

Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum ​Serum Separator Tube (SST) ​Red Top Tube (RTT) ​0.5 mL ​0.4 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​Refrigerate (preferred) ​21 days
​Frozen ​21 days
Rejection Criteria
Gross Hemolysis
​Gross Lipemia
Interference

A positive result indicates the presence of measurable IgG antibodies to RNA polymerase III, but does not unequivocally establish the diagnosis of systemic sclerosis or other autoimmune disease.

The level of RNA polymerase III autoantibodies does not indicate the severity of disease in patients with systemic sclerosis.

The presence of immune complexes or other immunoglobulin aggregates in the patient specimen may cause an increased level of nonspecific binding and produce false-positive results with this assay.

 
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories ​Wednesday ​1 day ​Enzyme-Linked Immunosorbent Assay (ELISA)
Reference Lab
Reference Range Information
Performing Location Reference Range
​Mayo Clinic Laboratories <20.0 U (negative)
20.0-39.9 U (weak positive)
40.0-80.0 U (moderate positive)
>80.0 U (strong positive)
Interpretation

A positive result supports a possible diagnosis of systemic sclerosis. This autoantibody is strongly associated with diffuse cutaneous scleroderma and with an increased risk of acute renal crisis.

A negative result indicates no detectable IgG antibodies to RNA polymerase III, but does not rule out the possibility of systemic sclerosis (11%-23% sensitivity).

Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
83516 ​1
Synonyms/Keywords
RNA Polymerase III Ab, IgG, S
Ordering Applications
Ordering Application Description
​COM RNA Polymerase III Antibodies, IgG, Serum (RNAP)
​Centricity RNA Polymerase III Antibodies, IgG, Serum (RNAP)
​Cerner RNA Polymerase III Antibodies, IgG, Serum (RNAP)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum ​Serum Separator Tube (SST) ​Red Top Tube (RTT) ​0.5 mL ​0.4 mL
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​Refrigerate (preferred) ​21 days
​Frozen ​21 days
Rejection Criteria
Gross Hemolysis
​Gross Lipemia
Interference

A positive result indicates the presence of measurable IgG antibodies to RNA polymerase III, but does not unequivocally establish the diagnosis of systemic sclerosis or other autoimmune disease.

The level of RNA polymerase III autoantibodies does not indicate the severity of disease in patients with systemic sclerosis.

The presence of immune complexes or other immunoglobulin aggregates in the patient specimen may cause an increased level of nonspecific binding and produce false-positive results with this assay.

 
Useful For

Evaluating patients suspected of having systemic sclerosis, when used in conjunction with centromere and Scl70 antibodies.

Providing diagnostic and prognostic information in patients with systemic sclerosis.

Reference Range Information
Performing Location Reference Range
​Mayo Clinic Laboratories <20.0 U (negative)
20.0-39.9 U (weak positive)
40.0-80.0 U (moderate positive)
>80.0 U (strong positive)
Interpretation

A positive result supports a possible diagnosis of systemic sclerosis. This autoantibody is strongly associated with diffuse cutaneous scleroderma and with an increased risk of acute renal crisis.

A negative result indicates no detectable IgG antibodies to RNA polymerase III, but does not rule out the possibility of systemic sclerosis (11%-23% sensitivity).

For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories ​Wednesday ​1 day ​Enzyme-Linked Immunosorbent Assay (ELISA)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
83516 ​1
For most current information refer to the Marshfield Laboratory online reference manual.